Loading…

Virus-Like-Vaccines against HIV

Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2018-02, Vol.6 (1), p.10
Main Authors: Andersson, Anne-Marie C, Schwerdtfeger, Melanie, Holst, Peter J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53
cites cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53
container_end_page
container_issue 1
container_start_page 10
container_title Vaccines (Basel)
container_volume 6
creator Andersson, Anne-Marie C
Schwerdtfeger, Melanie
Holst, Peter J
description Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.
doi_str_mv 10.3390/vaccines6010010
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33</doaj_id><sourcerecordid>2026484134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</originalsourceid><addsrcrecordid>eNpdkUtrGzEURkVJaYKbdXetIZtuppZ09dwEQkhig6Gb1nQnJI3GkTOecaWZQP59ldgNcYRAQjr3cKUPoS8E_wDQePZovY9dyAITXOYHdEaxFBVo-HPyZn-KznPe4DI0ASXkJ3RKNQPNpDhD31YxjblaxodQrQ6-qV3b2OVhOl-sPqOPjW1zOD-sE_T79ubX9bxa_rxbXF8tK8-UHCpnGfcEtNW1sAQ8BaUkEOy5ck5xoKThguCgRAHA-kZR7rBTpY1GSMthghZ7b93bjdmluLXpyfQ2mpeDPq2NTUP0bTDUU-cDbpyuHROKKc6lqFnNAyOiBiiuy71rN7ptqH3ohmTbI-nxTRfvzbp_NFxJJjgpgu8HQer_jiEPZhuzD21ru9CP2VCMKSVKC1nQi3foph9TV76qUFQwxQiwQs32lE99zik0r80QbJ6zNO-yLBVf377hlf-fHPwDPE-Y1A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2026484134</pqid></control><display><type>article</type><title>Virus-Like-Vaccines against HIV</title><source>Access via ProQuest (Open Access)</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</creator><creatorcontrib>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</creatorcontrib><description>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines6010010</identifier><identifier>PMID: 29439476</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>antibodies ; CD4 antigen ; CD8 antigen ; Coding ; Cytotoxicity ; Drug delivery systems ; Expression vectors ; Glycoproteins ; HIV ; Human immunodeficiency virus ; Immune response ; Immune response (cell-mediated) ; Immune response (humoral) ; Immune system ; Immunogenicity ; Lymphocytes ; Lymphocytes T ; Particle production ; Replication ; Review ; Safety ; T cells ; Vaccines ; Vaccinia ; virus vectors ; virus-like-particles ; virus-like-vaccines ; Viruses</subject><ispartof>Vaccines (Basel), 2018-02, Vol.6 (1), p.10</ispartof><rights>Copyright MDPI AG 2018</rights><rights>2018 by the authors. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</citedby><cites>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2026484134/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2026484134?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29439476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andersson, Anne-Marie C</creatorcontrib><creatorcontrib>Schwerdtfeger, Melanie</creatorcontrib><creatorcontrib>Holst, Peter J</creatorcontrib><title>Virus-Like-Vaccines against HIV</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</description><subject>antibodies</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Coding</subject><subject>Cytotoxicity</subject><subject>Drug delivery systems</subject><subject>Expression vectors</subject><subject>Glycoproteins</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Particle production</subject><subject>Replication</subject><subject>Review</subject><subject>Safety</subject><subject>T cells</subject><subject>Vaccines</subject><subject>Vaccinia</subject><subject>virus vectors</subject><subject>virus-like-particles</subject><subject>virus-like-vaccines</subject><subject>Viruses</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkUtrGzEURkVJaYKbdXetIZtuppZ09dwEQkhig6Gb1nQnJI3GkTOecaWZQP59ldgNcYRAQjr3cKUPoS8E_wDQePZovY9dyAITXOYHdEaxFBVo-HPyZn-KznPe4DI0ASXkJ3RKNQPNpDhD31YxjblaxodQrQ6-qV3b2OVhOl-sPqOPjW1zOD-sE_T79ubX9bxa_rxbXF8tK8-UHCpnGfcEtNW1sAQ8BaUkEOy5ck5xoKThguCgRAHA-kZR7rBTpY1GSMthghZ7b93bjdmluLXpyfQ2mpeDPq2NTUP0bTDUU-cDbpyuHROKKc6lqFnNAyOiBiiuy71rN7ptqH3ohmTbI-nxTRfvzbp_NFxJJjgpgu8HQer_jiEPZhuzD21ru9CP2VCMKSVKC1nQi3foph9TV76qUFQwxQiwQs32lE99zik0r80QbJ6zNO-yLBVf377hlf-fHPwDPE-Y1A</recordid><startdate>20180211</startdate><enddate>20180211</enddate><creator>Andersson, Anne-Marie C</creator><creator>Schwerdtfeger, Melanie</creator><creator>Holst, Peter J</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180211</creationdate><title>Virus-Like-Vaccines against HIV</title><author>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>antibodies</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Coding</topic><topic>Cytotoxicity</topic><topic>Drug delivery systems</topic><topic>Expression vectors</topic><topic>Glycoproteins</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Particle production</topic><topic>Replication</topic><topic>Review</topic><topic>Safety</topic><topic>T cells</topic><topic>Vaccines</topic><topic>Vaccinia</topic><topic>virus vectors</topic><topic>virus-like-particles</topic><topic>virus-like-vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andersson, Anne-Marie C</creatorcontrib><creatorcontrib>Schwerdtfeger, Melanie</creatorcontrib><creatorcontrib>Holst, Peter J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andersson, Anne-Marie C</au><au>Schwerdtfeger, Melanie</au><au>Holst, Peter J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virus-Like-Vaccines against HIV</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2018-02-11</date><risdate>2018</risdate><volume>6</volume><issue>1</issue><spage>10</spage><pages>10-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>29439476</pmid><doi>10.3390/vaccines6010010</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2018-02, Vol.6 (1), p.10
issn 2076-393X
2076-393X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33
source Access via ProQuest (Open Access); IngentaConnect Journals; PubMed Central
subjects antibodies
CD4 antigen
CD8 antigen
Coding
Cytotoxicity
Drug delivery systems
Expression vectors
Glycoproteins
HIV
Human immunodeficiency virus
Immune response
Immune response (cell-mediated)
Immune response (humoral)
Immune system
Immunogenicity
Lymphocytes
Lymphocytes T
Particle production
Replication
Review
Safety
T cells
Vaccines
Vaccinia
virus vectors
virus-like-particles
virus-like-vaccines
Viruses
title Virus-Like-Vaccines against HIV
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virus-Like-Vaccines%20against%20HIV&rft.jtitle=Vaccines%20(Basel)&rft.au=Andersson,%20Anne-Marie%20C&rft.date=2018-02-11&rft.volume=6&rft.issue=1&rft.spage=10&rft.pages=10-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines6010010&rft_dat=%3Cproquest_doaj_%3E2026484134%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2026484134&rft_id=info:pmid/29439476&rfr_iscdi=true